16.02
-0.99%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Changchun BCHT Biotechnology
Its shares trade on Shanghai under the ticker 688276.SS. It has been listed since 25 June 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥591.8m and a net loss of CN¥272.1m. At that date it held total assets of CN¥5.07bn and shareholders' equity of CN¥3.85bn.
Changchun BCHT Biotechnology Co. engages in the research and development, production and sale of human vaccines. The company is headquartered in Changchun, Jilin. The company went IPO on 2021-06-25. The firm is mainly engaged in the research and development, production and sales of human vaccines. The firm has three approved vaccine products: varicella vaccine, rabies vaccine and freeze-dried nasal spray flu vaccine. The firm also has other vaccines under development and fully human monoclonal antibody under development for the prevention and control of infectious diseases. The firm mainly conducts business within the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 25 Jun 2021
- Employees
- 1,252
- Website
- bchtpharm.com ↗
Leadership
Pay as last reported
- Mr. Zhaofeng MengChief Financial OfficerCN¥2.1m
- Mr. Wei KongGeneral Manager, Director, since 2004CN¥4.2m
- Mr. Chunlai JiangExecutive Deputy General Manager, DirectorCN¥3.4m
- Mr. Dawei LiuDeputy General ManagerCN¥2.7m
- Mr. Wanfeng SunDeputy General Manager
- Ms. Wei WeiDeputy General ManagerCN¥2.8m
- Mr. Zhe ZhangSecretary of the BoardCN¥1.4m
- Mr. Yuntao JiangDirector
- Mr. Xiufeng LiDirector
- Mr. Yan ZhangDirector
- Mr. Xinggong ZhuDirector
- Mr. Xuetian LiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 71
- Environment
- 77
- Social
- 81
- Governance
- 53
- Direct emissions (scope 1)
- 21,831 t
- Energy emissions (scope 2)
- 23,731.88 t
- Women in the workforce
- 40.81633%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Changchun BCHT Biotechnology Co employs 1,252 full-time employees in vaccine R&D and production.
- The company has three approved vaccine products including varicella and rabies vaccines.
- Changchun BCHT Biotechnology Co focuses on domestic market sales for human vaccines.
Weaknesses
- The company has no international market presence beyond China's domestic market.
- Changchun BCHT Biotechnology Co has only three approved vaccine products.
- The firm's development pipeline includes only one fully human monoclonal antibody.
Opportunities
- Changchun BCHT Biotechnology Co could expand its vaccine portfolio with additional approved products.
- The domestic Chinese market offers growth potential for human vaccine sales.
- The company may develop new vaccines for infectious disease prevention and control.
Threats
- Changchun BCHT Biotechnology Co faces competition from other domestic vaccine producers.
- The company's reliance on the domestic market increases vulnerability to local regulatory changes.
- Changchun BCHT Biotechnology Co has no international market presence to mitigate regional risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.